Skip Navigation

Cardiovascular Research 2004 62(2):287-298; doi:10.1016/j.cardiores.2004.01.019
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dhein, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dhein, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Pharmacology of gap junctions in the cardiovascular system

Stefan Dhein*

Clinic for Cardiac Surgery, Heart Centre Leipzig, University of Leipzig, Struempellstr. 39, 04289 Leipzig, Germany

* Tel.: +49-341-1044; fax: +49-341-1452. Email address: dhes{at}medizin.uni-leipzig.de

Gap junction channels provide the basis for intercellular communication and play an important physiological role in the cardiovascular system for maintenance of the normal cardiac rhythm, regulation of vascular tone, endothelial function and myoendothelial interaction as well as for metabolic interchange between the cells. Thus, pharmacological influence on these channels might help to elucidate their role in physiology and pathophysiology and might reveal new therapeutic approaches. The gap junction conductance between two cells is defined by the number of channels, the single channel conductance and the mean open and closed time. In principle, it is possible pharmacologically to induce closing of the channels, to change preferred single channel conductance, to open channels (or to keep them open), and to regulate the expression, synthesis, assembly and degradation of the channels thereby controlling the number of channels. This review describes the various substances affecting these parameters and outlines the possible pharmacological use of such drugs.

KEYWORDS Gap junctions; Connexin; Pharmacology; Cardiovascular; Regulation

Time for primary review 26 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
L. P. Veliz, F. G. Gonzalez, B. R. Duling, J. C. Saez, and M. P. Boric
Functional role of gap junctions in cytokine-induced leukocyte adhesion to endothelium in vivo
Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1056 - H1066.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
B Alldredge
Clinical connexions
J. Clin. Pathol., August 1, 2008; 61(8): 885 - 890.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
X. Lin, C. Zemlin, J. K. Hennan, J. S. Petersen, and R. D. Veenstra
Enhancement of ventricular gap-junction coupling by rotigaptide
Cardiovasc Res, August 1, 2008; 79(3): 416 - 426.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.